SHC · Sotera Health Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $280.05M | - | $311.31M | $294.34M | $254.52M | - | $285.47M | $276.59M | $248.18M | - |
| Cost of Revenue | $132.98M | - | $133.75M | $127.72M | $119.09M | - | $127.44M | $123.80M | $121.06M | - |
| Gross Profit | $147.07M | - | $177.56M | $166.62M | $135.43M | - | $158.02M | $152.79M | $127.11M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $68.21M | - | $63.29M | $68.89M | $63.06M | - | $62.01M | $60.58M | $58.21M | - |
| Total Operating Expenses | - | - | - | - | - | - | $77.52M | $75.99M | $73.94M | - |
| D&A | $25.21M | - | - | - | $22.13M | - | - | - | $20.31M | - |
| Operating Income | $42.61M | - | $72.94M | $18.90M | ($14.82M) | - | $80.51M | $76.80M | $53.17M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $16.02M | - | $24.54M | $10.94M | ($1.56M) | - | $25.76M | $6.39M | $4.69M | - |
| Net Income | $26.59M | - | $48.40M | $7.96M | ($13.26M) | - | $17.00M | $8.75M | $6.30M | - |
| EPS - Basic | $0.09 | - | $0.17 | $0.03 | ($0.05) | - | $0.06 | $0.03 | $0.02 | - |
| EPS - Diluted | $0.09 | - | $0.17 | $0.03 | ($0.05) | - | $0.06 | $0.03 | $0.02 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $314.15M | $344.62M | $299.19M | $332.44M | $304.39M | $277.24M | $306.74M | $246.08M | $261.13M | $296.41M |
| Accounts Receivable | $137.26M | $139.33M | $142.39M | $136.56M | $128.07M | $140.33M | $130.12M | $123.66M | $111.07M | $147.70M |
| Inventory | $57.49M | $54.38M | $49.87M | $59.95M | $61.05M | $49.16M | $53.65M | $57.87M | $51.34M | $48.32M |
| Accounts Payable | $76.69M | $77.96M | $61.39M | $63.66M | $70.11M | $55.10M | $70.75M | $64.49M | $61.58M | $71.04M |
| Current Assets | $585.97M | $613.41M | $577.82M | $608.17M | $554.99M | $526.04M | $563.61M | $497.68M | $487.18M | $557.24M |
| Total Assets | $3.24B | $3.26B | $3.19B | $3.22B | $3.10B | $3.07B | $3.15B | $3.06B | $3.06B | $3.13B |
| Current Liabilities | $207.80M | $249.58M | $242.40M | $246.32M | $225.99M | $191.00M | $195.54M | $169.63M | $152.34M | $230.65M |
| Long-term Debt | $2.12B | $2.13B | $2.13B | $2.20B | $2.21B | $2.21B | $2.21B | $2.21B | $2.22B | $2.22B |
| Total Liabilities | $2.61B | $2.66B | $2.64B | $2.71B | $2.68B | $2.67B | $2.68B | $2.64B | $2.63B | $2.69B |
| Stockholders' Equity | $622.50M | $606.03M | $550.47M | $511.28M | $414.09M | $404.91M | $470.16M | $422.76M | $429.39M | $443.73M |
| Retained Earnings | ($505.50M) | ($532.09M) | ($566.94M) | ($615.34M) | ($623.30M) | ($610.04M) | ($622.37M) | ($639.36M) | ($648.12M) | ($654.44M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $29.43M | - | - | - | $55.52M | - | - | - | $9.70M | - |
| Investing Cash Flow | ($45.13M) | - | - | - | ($19.88M) | - | - | - | ($34.85M) | - |
| Financing Cash Flow | ($12.78M) | - | - | - | ($8.09M) | - | - | - | ($11.94M) | - |
| CapEx | $46.17M | - | - | - | $19.92M | - | - | - | $34.89M | - |
| Free Cash Flow | ($16.73M) | - | - | - | $35.60M | - | - | - | ($25.19M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 52.5% | - | 57.0% | 56.6% | 53.2% | - | 55.4% | 55.2% | 51.2% | - |
| Operating margin | 15.2% | - | 23.4% | 6.4% | -5.8% | - | 28.2% | 27.8% | 21.4% | - |
| EBITDA margin | 24.2% | - | - | - | 2.9% | - | - | - | 29.6% | - |
| Net margin | 9.5% | - | 15.5% | 2.7% | -5.2% | - | 6.0% | 3.2% | 2.5% | - |
| Free cash flow margin | -6.0% | - | - | - | 14.0% | - | - | - | -10.2% | - |
| FCF / Net income | -0.63 | - | - | - | -2.68 | - | - | - | -4.00 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 24.4% | - | 20.3% | 23.4% | 24.8% | - | 21.7% | 21.9% | 23.5% | - |
| Effective tax rate | 37.6% | - | 33.6% | 57.9% | - | - | 60.2% | 42.2% | 42.7% | - |
| Return on assets | 0.8% | - | 1.5% | 0.2% | -0.4% | - | 0.5% | 0.3% | 0.2% | - |
| Return on equity | 4.3% | - | 8.8% | 1.6% | -3.2% | - | 3.6% | 2.1% | 1.5% | - |
| Return on invested capital | 1.0% | - | 1.8% | 0.3% | -0.4% | - | 1.5% | 1.7% | 1.1% | - |
| Liquidity | ||||||||||
| Current ratio | 2.82 | 2.46 | 2.38 | 2.47 | 2.46 | 2.75 | 2.88 | 2.93 | 3.20 | 2.42 |
| Quick ratio | 2.54 | 2.24 | 2.18 | 2.23 | 2.19 | 2.50 | 2.61 | 2.59 | 2.86 | 2.21 |
| Cash ratio | 1.51 | 1.38 | 1.23 | 1.35 | 1.35 | 1.45 | 1.57 | 1.45 | 1.71 | 1.29 |
| Leverage | ||||||||||
| Debt / Equity | 3.41 | 3.51 | 3.87 | 4.31 | 5.33 | 5.45 | 4.70 | 5.24 | 5.18 | 5.01 |
| Debt / Assets | 0.66 | 0.65 | 0.67 | 0.68 | 0.71 | 0.72 | 0.70 | 0.72 | 0.73 | 0.71 |
| Debt / EBITDA | 31.32 | - | - | - | 301.81 | - | - | - | 30.28 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 5.20 | 5.38 | 5.79 | 6.29 | 7.48 | 7.59 | 6.70 | 7.23 | 7.13 | 7.05 |
| Liabilities / Assets | 0.81 | 0.81 | 0.83 | 0.84 | 0.87 | 0.87 | 0.85 | 0.86 | 0.86 | 0.86 |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.10 | 0.09 | 0.08 | - | 0.09 | 0.09 | 0.08 | - |
| Inventory turnover | 2.31 | - | 2.68 | 2.13 | 1.95 | - | 2.38 | 2.14 | 2.36 | - |
| Days sales outstanding | 179d | - | 167d | 169d | 184d | - | 166d | 163d | 163d | - |
| Days inventory outstanding | 158d | - | 136d | 171d | 187d | - | 154d | 171d | 155d | - |
| Days payable outstanding | 210d | - | 168d | 182d | 215d | - | 203d | 190d | 186d | - |
| Cash conversion cycle | 126d | - | 136d | 159d | 156d | - | 117d | 144d | 132d | - |
| Valuation | ||||||||||
| P / E | 159.3x | - | 92.5x | 370.7x | - | - | 278.3x | 395.7x | 600.5x | - |
| P / B | 6.6x | - | 8.2x | 6.2x | 8.0x | - | 10.1x | 8.0x | 7.9x | - |
| P / S | 14.7x | - | 14.5x | 10.8x | 13.0x | - | 16.7x | 12.2x | 13.7x | - |
| EV / EBITDA | 87.5x | - | - | - | 712.6x | - | - | - | 73.2x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.0% | - | 9.1% | 6.4% | 2.6% | - | 8.5% | 8.3% | 12.5% | - |
| Revenue CAGR (3y) | 8.3% | - | 7.8% | 3.3% | 2.4% | - | 12.6% | 3.2% | 9.7% | - |
| Revenue CAGR (5y) | 8.3% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 8.6% | - | 12.4% | 9.1% | 6.5% | - | 8.2% | 9.5% | 14.0% | - |
| Operating income growth (YoY) | - | - | -9.4% | -75.4% | - | - | 5.8% | 21.5% | 59.4% | - |
| Net income growth (YoY) | - | - | 184.7% | -9.0% | - | - | - | -62.8% | 123.1% | - |
| EPS growth (YoY) | - | - | 183.3% | 0.0% | - | - | - | -62.5% | 100.0% | - |
| EPS CAGR (3y) | 108.0% | - | 23.6% | -35.2% | - | - | -15.7% | -41.5% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -126.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 50.3% | 49.7% | 17.1% | 20.9% | -3.6% | -8.7% | 24.6% | 1.1% | 18.9% | 26.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.16B totalSterigenics$755.78M · 65.2%
Nelson Labs$220.22M · 19.0%
Nordion$182.82M · 15.8%
Product / service
$1.16B totalService$995.76M · 85.6%
Product$167.86M · 14.4%
Geographic
$1.16B totalUS$629.54M · 54.1%
Europe$232.18M · 20.0%
CA$221.95M · 19.1%
Other Geographical Areas$79.95M · 6.9%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing Sotera Health Co against the 5 most active filers in the same SIC group.